Adagene unveils board, management appointments to support pipeline growth
Adagene unveils board, management appointments to support pipeline growth
KUALA LUMPUR, Feb 3 -- Adagene Inc (Adagene), a company transforming the discovery and development of antibody-based therapies, announced board and management appointments aimed at supporting the company’s pipeline growth and corporate development.
According to a statement, the appointments include Liu Yuwen as a new independent board member and member of the Audit Committee; Jiping Zha, M.D., Ph.D. as Executive Vice President of Clinical Development; and Dana Hu-Lowe, Ph.D., as Vice President of Global Product Team Leadership.
“As we prepare for rapid growth in our pipeline of antibody-based therapeutics, I am delighted to welcome Yuwen to our board, and Jiping and Dana to our global leadership team,” said Co-Founder, Chief Executive Officer and Chairman of the Board of Adagene, Peter Luo, Ph.D.
“A tremendous growth opportunity is before us to leverage our AI-powered antibody technology platform and transformative clinical and preclinical pipelines. This talented team brings deep industry knowledge, strong professional networks and highly relevant experience to help us realise this mission.”
Liu Yuwen is a leading advocate for the biotechnology, biopharmaceutical and medical technology industries, with over 20 years as an entrepreneur, adviser and investor.
Meanwhile, Dr Zha is a physician scientist with over 20 years of drug discovery and development experience with deep expertise in disease biology, translational sciences, biomarker discovery, precision medicine and clinical development.
Dr Hu-Lowe has more than 20 years of experience in oncology drug discovery, pharmacology, translational research, and clinical development, including project and strategic alliance management.
Drs Zha and Hu-Lowe have joined to lead clinical development of the company, taking over responsibilities of Dr Hua Gong, M.D., Ph.D., Chief Operating Officer and Head of Precision Medicine, who has resigned to pursue another opportunity.
Separately, Steven Fischkoff, M.D., has retired and is stepping down from his role as interim Chief Medical Officer. Dr Fischkoff will remain a member of the company’s Scientific and Strategic Advisory Board.
Additionally, Chief Financial Officer Raymond Tam will continue as director for another one-year term. Tam has served as the company’s CFO since 2019 and director since 2021.
-- BERNAMA
